SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name a	1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer																	
Blischak Matthew P.					Fir	Finch Therapeutics Group, Inc. [FNCH]							(Che	(Check all applicable) Director			le) 10% Owne	
						3. Date of Earliest Transaction (Month/Day/Year)								C Officer below)	(give title		Other (s below)	pecify
(Last) (First) (Middle) C/O FINCH THERAPEUTICS GROUP, INC.						06/08/2023								Cl	Chief Executive Officer			
75 STATE STREET, SUITE 100					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
					-								2	X Form filed by One Reporting Person				
(Street) BOSTON MA 02109													Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication																	
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												to					
		Tal	ble I - Nor	n-Deri	vative	e Se	ecuritie	s Ao	cquired, C	Disp	osed o	of, or Be	eneficiall	y Owned			4	
1. Title of Security (Instr. 3) 2. Transac Date (Month/D					Execution Date		e, Transaction Dispose Code (Instr. 5)		ırities Acquired (A) or æd Of (D) (Instr. 3, 4 ar		5. Amour Securitie Beneficia Owned F	s ally ollowing	Form ly (D) of		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	t (A) or Price		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, Tr curity or Exercise (Month/Day/Year) if any Co			Transac Code (In	ansaction Derivative ode (Instr. Securities			Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$0.285	06/08/2023			A		962,899		(1)	06	/07/2033	Common Stock	962,899	\$0.00	962,89	9	D	

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to this option shall vest on June 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.

Remarks:

By: /s/ Matthew P. Blischak

** Signature of Reporting Person

06/09/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.